ArticleBipolar disorders2017
Serum phosphatidylinositol as a biomarker for bipolar disorder liability.
Article in Bipolar disorders, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 28 citations in OpenAlex.
- Discrimination of Bipolar Disorder and Schizophrenia Patients Based on LC-HRMS Lipidomics.Metabolites · 2026Article
- Changes in the endoplasmic reticulum‑mitochondria communication in dermal fibroblasts from early‑stage bipolar disorder patients: Skin‑brain axis as a new route to understand the pathophysiology of mental illness?International journal of molecular medicine · 2025Article
- Cognitive impairment in bipolar disorder associated with abnormal serum short-chain fatty acids and cytokines.BMC psychiatry · 2025Article
- The Role of Extracellular Vesicles in Neuropsychiatric Disorders.Advanced pharmaceutical bulletin · 2025Review
- Plasma and Serum LC-MS Lipidomic Fingerprints of Bipolar Disorder and Schizophrenia.International journal of molecular sciences · 2025Review
- Marked alteration of phosphoinositide signaling-associated molecules in postmortem prefrontal cortex with bipolar disorder.Neuropsychopharmacology reports · 2024Article
- Untargeted Lipidomics Study of Bipolar Disorder Patients in Serbia.International journal of molecular sciences · 2023Article
- Adaptation of Lipid Profiling in Depression Disease and Treatment: A Critical Review.International journal of molecular sciences · 2022Review
- Alterations in the Plasma Lipidome of Adult Women With Bipolar Disorder: A Mass Spectrometry-Based Lipidomics Research.Frontiers in psychiatry · 2022Article
- Metabolomic Identification of Serum Exosome-Derived Biomarkers for Bipolar Disorder.Oxidative medicine and cellular longevity · 2022Article
- Alterations of Plasma Lipids in Adult Women With Major Depressive Disorder and Bipolar Depression.Frontiers in psychiatry · 2022Article
- Modulation of the gut microbiota and lipidomic profiles by black chokeberry (Frontiers in nutrition · 2022Article
- Characterization of the COPD Salivary Fingerprint through Surface Enhanced Raman Spectroscopy: A Pilot Study.Diagnostics (Basel, Switzerland) · 2021Article
- Neurocognitive impairment in type 2 diabetes: evidence for shared genetic aetiology.Diabetologia · 2020Article
- Toward Complete Structure Elucidation of Glycerophospholipids in the Gas Phase through Charge Inversion Ion/Ion Chemistry.Analytical chemistry · 2020Article
- Metabolic Profiling in Bipolar Disorder Patients During Depressive Episodes.Frontiers in psychiatry · 2020Article
- Article
- Genetic Overlap Between Alzheimer's Disease and Bipolar Disorder Implicates the MARK2 and VAC14 Genes.Frontiers in neuroscience · 2019Article
- Disentangling the genetic overlap between cholesterol and suicide risk.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 6 institutions in 2 countries.
Funding
Abstract
objectivesIndividuals with bipolar disorder (BPD) exhibit alterations in their phospholipid levels. It is unclear whether these alterations are a secondary consequence of illness state, or if phospholipids and illness risk overlap genetically. If the latter were true, then phospholipids might provide key insights into the pathophysiology of the illness. Therefore, we rank-ordered phospholipid classes by their genetic overlap with BPD risk in order to establish which class might be most informative in terms of increasing our understanding of illness pathophysiology.
methodsAnalyses were conducted in a sample of 558 individuals, unselected for BPD, from 38 extended pedigrees (average family size=14.79, range=2-82). We calculated a coefficient of relatedness for all family members of nine individuals with BPD in the sample (N=185); this coefficient was set to be zero in unrelated individuals (N=373). Then, under an endophenotype ranking value (ERV) approach, this scalar index was tested against 13 serum-based phospholipid concentrations in order to rank-order lipid classes by their respective overlap with BPD risk.
resultsThe phosphatidylinositol class was significantly heritable (h
conclusionsWe identified a peripheral biomarker, serum-based phosphatidylinositol, which exhibits a significant association with BPD risk. Therefore, given that phosphatidylinositol and BPD risk share partially common etiology, it seems that this lipid class warrants further investigation, not only in terms of treatment, but also as a promising diagnostic and risk marker.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.